Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

An AI system developed to predict a patient's response to immunotherapy could help "democratize" access to the pricey drugs ...